Tuesday, 26 October 2021 08:33 GMT

KFSHRC Successfully Applies Iodine Radioisotope to Treat Neuroblastoma


(MENAFN- Saudi Press Agency) Riyadh, October 3, 2021, SPA -- King Faisal Specialist Hospital and the Research Center (KFSHRC) in Riyadh has managed to apply an advanced technology of using Iodine-131 to control a rare type of cancer called neuroblastoma, which can affect newborns and children up to the age of five, where the hospital is the only one that uses this technology in the Arab world.
Blood Diseases Consultant and Pediatric Oncologist at KFSHRC Dr. Mahab Ayas said that this technology is composed of a radioactive element that is given to children through veins to help eliminate neuroblastoma when other ways fail to treat the disease, noting that treatments of this disease include chemical treatments, radioactive and immunity, which are all used before resorting to iodine radioisotope.
Dr. Ayas said that this disease is among rare cancers that affect children under the age of five due to nerve cells that did not develop enough in several organs of the patient's body, noting that the disease is lethal if it is not treated, and if the patient's response to treatment was low, treatment chances will also be low, adding that applying this technology has contributed to controlling this disease.
He added that this used to be a terminal illness and curing rates were very low during the past four decades, but the last two decades, through conducting intensified chemical, X-ray and surgical procedures and self-bone marrow transplants, witnessed the ability of treating the disease despite having some cases that do not respond to treatment.
--SPA
13:28 LOCAL TIME 10:28 GMT
0011

MENAFN03102021000078011016ID1102906872


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.